AKTX
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
19.04M
GET INTRADAY SIGNALS
AKTX Trading results, last 6 months
AI Robots NameP/LEntry Price, $Profit, $/%
69 days until earnings call
+Compare
AKTX
Stock ticker:
NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
19.04M

AKTX Price Prediction, Akari Therapeutics plc AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

GET INTRADAY SIGNALS
AKTX Trading results, last 6 months
AI Robots NameP/LEntry Price, $Profit, $/%
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
AI
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EDT Mar 23, 2023

AKTX in upward trend: price may ascend as a result of having broken its lower Bollinger Band on March 20, 2023

AKTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 24 of 27 cases where AKTX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AKTX's RSI Indicator exited the oversold zone, of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for AKTX just turned positive on March 23, 2023. Looking at past instances where AKTX's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AKTX advanced for three days, in of 210 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for AKTX entered a downward trend on March 23, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.287) is normal, around the industry mean (21.708). P/E Ratio (0.000) is within average values for comparable stocks, (125.534). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.749). Dividend Yield (0.000) settles around the average of (0.028) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (303.071).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. AKTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

AI
A.I. Advisor
published Earnings

AKTX is expected to report earnings to fall 12.50% to -3 cents per share on March 22

Akari Therapeutics plc AKTX Stock Earnings Reports
Q4'22
Est.
$-0.04
Q3'22
Est.
$-0.04
Q4'21
Est.
$0.00
Q3'21
Est.
$0.00
Q2'21
Est.
$0.00
The last earnings report on November 17 showed earnings per share of -3 cents, meeting the estimate of -3 cents. With 92.11K shares outstanding, the current market capitalization sits at 19.04M.
AI
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.96B. The market cap for tickers in the group ranges from 160 to 331.75B. NONOF holds the highest valuation in this group at 331.75B. The lowest valued company is CDXI at 160.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -2%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was 0%. CALC experienced the highest price growth at 1,040%, while MMIRF experienced the biggest fall at -92%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was -33% and the average quarterly volume growth was -64%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 62
SMR Rating: 92
Profit Risk Rating: 94
Seasonality Score: -2 (-100 ... +100)
AI
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
AI
A.I.Advisor
published price charts
AI
A.I. Advisor
published General Information

General Information

a developer of biopharmaceuticals

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
75/76 Wimpole Street
Phone
+44 2080040270
Employees
9
Web
https://www.akaritx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AZTA41.600.32
+0.78%
Azenta
FGI1.87N/A
N/A
FGI Industries Ltd
SSP8.90-0.06
-0.67%
EW Scripps Company (The)
BSBR4.82-0.11
-2.23%
Banco Santander (Brasil) SA
MFIN7.65-0.21
-2.67%
Medallion Financial Corp

AKTX and

Correlation & Price change

A.I.dvisor tells us that AKTX and COCP have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AKTX and COCP's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKTX
1D Price
Change %
AKTX100%
+2.32%
COCP - AKTX
23%
Poorly correlated
-0.54%
CANF - AKTX
22%
Poorly correlated
-1.77%
LPTX - AKTX
21%
Poorly correlated
-1.49%
GOVX - AKTX
21%
Poorly correlated
-6.20%
IMTX - AKTX
20%
Poorly correlated
-3.71%
More